Highly diluted medication reduces parasitemia and improves experimental infection evolution by Trypanosoma cruzi

Abstract

BackgroundThere is no published information about the use of different protocols to administer a highly diluted medication.Evaluate the effect of different protocols for treatment with biotherapic T. cruzi 17 dH (BIOTTc17dH) on clinical/parasitological evolution of mice infected with T. cruzi-Y strain.MethodsA blind, randomized controlled trial was performed twice, using 60 28-day-old male Swiss mice infected with T. cruzi-Y strain, in five treatment groups: CI - treated with a 7% ethanol-water solution, diluted in water (10 μL/mL) ad libitum; BIOTPI - treated with BIOTTc17dH in water (10 μL/mL) ad libitum during a period that started on the day of infection; BIOT4DI - treated with BIOTTc17dH in water (10 μL/mL) ad libitum beginning on the 4th day of infection; BIOT4-5–6 - treated with BIOTTc17dH by gavage (0.2 mL/ animal/day) on the 4th, 5th and 6th days after infection; BIOT7-8–9 - treated with BIOTTc17dH by gavage (0.2 mL/ animal/day) on the 7th, 8th and 9th days after infection. We evaluated: parasitemia; total parasitemia (Ptotal); maximum peak of parasites; prepatent period (PPP) - time from infection to detection of the parasite in blood; patent period (PP) - period when the parasitemia can be detected in blood; clinical aspects; and mortality.ResultsParasitological parameters in the BIOTPI and mainly in the BIOT4PI group showed better evolution of the infection compared to the control group (CI), with lower Ptotal, lower maximum peak of parasites, higher PPP, lower PP and longer survival times. These animals showed stable body temperature and higher weight gain and water consumption, with more animals having normal-appearing fur for longer periods. In contrast, groups BIOT4-5–6 and BIOT7-8–9 showed worse evolution of the infection compared to the control group, considering both parasitological and clinical parameters. The correlation analysis combined with the other data from this study indicated that the prepatent period is the best parameter to evaluate the effect of a medication in this model.ConclusionsThe BIOT4DI group showed the best clinical and parasitological evolution, with lower parasitemia and a trend toward lower mortality and a longer survival period. The prepatent period was the best parameter to evaluate the effect of a medication in this model.

Associação de medicamentos homeopáticos promove diminuição da parasitemia e melhora clínica em camundongos infectados por Trypanosoma cruzi

“…Segundo prática clínica, o L. clavatum foi associado ao organoterápico 2 dias após a inoculação. Os medicamentos e seu veículo foram sucussionados, oferecidos diluídos em água (1mL/100mL) ad libitum, em bebedouro âmbar, por toda a noite, durante 16 horas (11).…”

Modulation of IFN-&gamma;, IL-4 and IL-17 Cytokines is Related to Parasitemia Control in Mice Infected by <i>Trypanosoma cruzi</i> and Treated with Biotherapy

“…The medications were diluted in water (10 µL/mL) and offered ad libitum in a sterile amber bottle according to Aleixo et al (2012) for 16 consecutive hours (medications were available to the animals from 5:00 PM to 9:00 AM). The treatment regimen was based on the actions of the medication that are linked to immunomodulatory effects on the specific evolution of the Y strain of T. cruzi in Swiss mice.…”

“…The treatment regimen was based on the actions of the medication that are linked to immunomodulatory effects on the specific evolution of the Y strain of T. cruzi in Swiss mice. Thus, this treatment regimen assessed the actions of the biotherapy and immune system before and after the presence of the parasite (Aleixo et al, 2012).…”

“…These preparations may have a pathological (nosode) or non-pathological (sarcode) origin (Brasil, 2011). The use of biotherapies as an intervention in murine infection with T. cruzi is a possible means to understand the effects of these highly diluted medications (Aleixo et al, 2012), since murine infection has been intensively studied and the mechanisms of resistance or susceptibility to infection have been sufficiently reported (Araújo-Jorge and Castro, 2000).…”

“…Previous studies have investigated the prophylactic and therapeutic effects of biotherapies in acute murine infection by this protozoan. These studies reported mainly parasitological, clinical, histopathological and hematological effects (Aleixo et al, 2012;Almeida et al, 2008;Ferraz et al, 2011Ferraz et al, , 2014aQueiroz et al, 2006;Sandri et al, 2015). However, only a few studies have directly investigated the immunomodulatory effects of biotherapies against T. cruzi infection (Almeida et al, 2008;Ferraz et al, 2014b;Queiroz et al, 2006;Sandri et al, 2015).…”